Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1993 1
1995 1
1996 1
2001 2
2002 3
2003 3
2004 1
2005 3
2006 7
2007 6
2008 3
2009 4
2010 2
2011 8
2012 6
2013 7
2014 9
2015 7
2016 4
2017 3
2018 2
2019 4
2020 3
2021 1
2022 6
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
Dynamic alpha factors: Prediction in time and evolution along reactors.
Bencsik D, Takács I, Rosso D. Bencsik D, et al. Water Res. 2022 Jun 1;216:118339. doi: 10.1016/j.watres.2022.118339. Epub 2022 Mar 21. Water Res. 2022. PMID: 35413625 Free article.
This factor varies depending on hydraulic and organic loading; such variance includes both time and spatial fluctuations. In standard design practice, it is often considered as a fixed number, or at best, a predefined time series. ...The authors' concept takes into …
This factor varies depending on hydraulic and organic loading; such variance includes both time and spatial fluctuations. In standard …
Randomized trial of intracardiac echocardiography-guided slow pathway ablation.
Kupo P, Saghy L, Bencsik G, Kohari M, Makai A, Vamos M, Benak A, Miklos M, Raileanu G, Schvartz N, Pap R. Kupo P, et al. J Interv Card Electrophysiol. 2022 Apr;63(3):709-714. doi: 10.1007/s10840-022-01126-y. Epub 2022 Jan 19. J Interv Card Electrophysiol. 2022. PMID: 35044581 Clinical Trial.
Crossover to ICE-guidance was allowed after 8 unsuccessful RF applications. RESULTS: Mapping plus ablation time (mean standard deviation: 18.8 16.1 min vs 11.6 15.0 min, p = 0.031), fluoroscopy time (median [interquartile range]: 4.9 [2.93-8.13] min vs. 1.8 [1.2-2.8 …
Crossover to ICE-guidance was allowed after 8 unsuccessful RF applications. RESULTS: Mapping plus ablation time (mean standard deviat …
Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.
Biernacki T, Kokas Z, Sandi D, Füvesi J, Fricska-Nagy Z, Faragó P, Kincses TZ, Klivényi P, Bencsik K, Vécsei L. Biernacki T, et al. Int J Mol Sci. 2022 Mar 21;23(6):3383. doi: 10.3390/ijms23063383. Int J Mol Sci. 2022. PMID: 35328802 Free PMC article. Review.
This is due to the permanent disability, cognitive impairment, and the enormous detrimental impact MS can exert on a patient's health-related quality of life. It is of great importance to recognise it in time and commence adequate treatment at an early stage. The currently …
This is due to the permanent disability, cognitive impairment, and the enormous detrimental impact MS can exert on a patient's health-relate …
[[Natalizumab therapy, 2013].
Karácsony M, Bencsik K, Vécsei L. Karácsony M, et al. Ideggyogy Sz. 2014 Jul 30;67(7-8):220-8. Ideggyogy Sz. 2014. PMID: 25509362 Review. Hungarian.
These data may lead the physician to decide to discontinue natalizumab treatment. The half-life of natalizumab is three months; during this time other therapies can not be administered and the patients encounter the rebound effect: as the patients receiving natalizumab the …
These data may lead the physician to decide to discontinue natalizumab treatment. The half-life of natalizumab is three months; during this …
Metagenomic Snapshots of Viral Components in Guinean Bats.
Hermida Lorenzo RJ, Cadar D, Koundouno FR, Juste J, Bialonski A, Baum H, García-Mudarra JL, Hakamaki H, Bencsik A, Nelson EV, Carroll MW, Magassouba N, Günther S, Schmidt-Chanasit J, Muñoz Fontela C, Escudero-Pérez B. Hermida Lorenzo RJ, et al. Microorganisms. 2021 Mar 15;9(3):599. doi: 10.3390/microorganisms9030599. Microorganisms. 2021. PMID: 33803988 Free PMC article.
Our study provides a snapshot of the viral diversity present in these bat species, with several novel viruses reported for the first time in bats, as well as some bat viruses closely related to known human or animal pathogens. ...
Our study provides a snapshot of the viral diversity present in these bat species, with several novel viruses reported for the first time …
Cardioprotective efficacy of limb remote ischaemic preconditioning in rats: discrepancy between a meta-analysis and a three-centre in vivo study.
Sayour NV, Brenner GB, Makkos A, Kiss B, Kovácsházi C, Gergely TG, Aukrust SG, Tian H, Zenkl V, Gömöri K, Szabados T, Bencsik P, Heinen A, Schulz R, Baxter GF, Zuurbier CJ, Vokó Z, Ferdinandy P, Giricz Z. Sayour NV, et al. Cardiovasc Res. 2023 Jun 13;119(6):1336-1351. doi: 10.1093/cvr/cvad024. Cardiovasc Res. 2023. PMID: 36718529 Free PMC article.
In addition, the systematic review showed methodological heterogeneity and insufficient reporting of study parameters in a high proportion of studies. CONCLUSION: We report for the first time the lack of cardioprotection by RIPC in rats, assessed in individually randomized …
In addition, the systematic review showed methodological heterogeneity and insufficient reporting of study parameters in a high proportion o …
Stem cell therapy extends incubation and survival time in prion-infected mice in a time window-dependant manner.
Relaño-Ginés A, Lehmann S, Bencsik A, Herva ME, Torres JM, Crozet CA. Relaño-Ginés A, et al. J Infect Dis. 2011 Oct 1;204(7):1038-45. doi: 10.1093/infdis/jir484. J Infect Dis. 2011. PMID: 21881119
Cell therapy that has been already tested in other neurodegenerative disorders therefore represents an interesting alternative approach. In this study, we showed for the first time in prion diseases that intracerebral transplantation of fetal neural stem cells significantl …
Cell therapy that has been already tested in other neurodegenerative disorders therefore represents an interesting alternative approach. In …
[TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS].
Bencsik K, Rózsa C, Vécsei L. Bencsik K, et al. Ideggyogy Sz. 2015 Mar 30;68(3-4):79-87. Ideggyogy Sz. 2015. PMID: 26434194 Review. Hungarian.
According to the TENERE study there were no significant differences observed between teriflunomide 14 mg and IFNbeta-alpha a s.c. in time to failure and annualized relapse rate but the treatment satisfaction domains of global satisfaction, side-effects and convenience were …
According to the TENERE study there were no significant differences observed between teriflunomide 14 mg and IFNbeta-alpha a s.c. in time …
Randomized trial of intracardiac echocardiography during cavotricuspid isthmus ablation.
Bencsik G, Pap R, Makai A, Klausz G, Chadaide S, Traykov V, Forster T, Sághy L. Bencsik G, et al. J Cardiovasc Electrophysiol. 2012 Sep;23(9):996-1000. doi: 10.1111/j.1540-8167.2012.02331.x. Epub 2012 Jul 19. J Cardiovasc Electrophysiol. 2012. PMID: 22812499 Clinical Trial.
CONCLUSIONS: ICE-guided ablation of the CTI significantly shortens the procedure and fluoroscopy time, markedly decreases radiation exposure, and time spent for ablation in comparison with fluoroscopy-only procedures. At the same time, visualization with ICE …
CONCLUSIONS: ICE-guided ablation of the CTI significantly shortens the procedure and fluoroscopy time, markedly decreases radiation e …
90 results